替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎患者疗效比较研究*

doi:10.3969/j.issn.1672-5069.2021.05.019

摘要/Abstract

摘要： 目的比较替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎(CHB)患者的疗效。方法 2016年6月～2020年3月我院诊治的CHB患者77例,均为接受过聚乙二醇α-干扰素治疗6个月后不应答的患者,其中接受替诺福韦治疗者41例,接受恩替卡韦治疗者36例。采用实时荧光定量PCR法检测血清HBV DNA载量,采用ELISA法检测血清HBsAg和HBeAg,使用CytoFLEX型流式细胞仪检测外周血CD4⁺和CD8⁺T淋巴细胞亚群。结果在治疗6个月和12个月末,替诺福韦治疗组血清ALT复常率分别为80.5%和90.2%,与恩替卡韦治疗组的77.8%和86.1%比,差异均无统计学意义(P＞0.05),血清HBV DNA转阴率分别为65.9%和95.1%,与恩替卡韦治疗组的63.9%和88.9%比,差异也无统计学意义(P＞0.05);替诺福韦治疗组外周血CD4⁺细胞百分比分别为(33.9±3.9)%和(38.6±5.6)%,显著高于恩替卡韦治疗的【(30.2±3.7)%和(35.1±3.6)%,P＜0.05】,CD4⁺/CD8⁺细胞比值分别为(1.2±0.1)和(1.5±0.1),显著高于恩替卡韦治疗组[(1.0±0.0)和(1.3±0.1),P＜0.05];在12个月的观察期内,替诺福韦治疗组耐药发生率为4.9%,与恩替卡韦治疗组的2.8%比,差异无统计学意义(x²=0.013,P=0.908)。结论替诺福韦与恩替卡韦治疗对聚乙二醇α-干扰素治疗不应答的CHB患者均可获得很好的疗效,但替诺福韦在提高免疫功能方面优于恩替卡韦治疗,延长疗程观察是否能提高血清HBeAg转阴率值得研究。

关键词: 慢性乙型肝炎, 聚乙二醇干扰素-α, 替诺福韦, 恩替卡韦, 再治疗

Abstract: Objective The aim of this study was to compare the efficacy of re-treatment of chronic hepatitis B (CHB) non-responders to pegylated interferon-α by tenofovir and entecavir. Methods 77 patients with CHB who were the non-responders to pegylated interferon-α were recruited in our hospital between June 2016 and March 2020, and divided into two groups, receiving tenofovir (n=41) or entecavir (n=36), respectively. Serum HBV DNA and HBsAg and HBeAg were assayed routinely, and peripheral blood lymphocyte subsets was detected by FCM. Results At the end of six and twelve month treatment, serum alanineaminotransferase normalization rates in tenofovir-treated patients were 80.5% and 90.2%, not significantly different as compared to 77.8% and 86.1% in entecavir-treated patients(P＞0.05), serum HBV DNA loss were 65.9% and 95.1%, also not significantly different as compared to 63.9% and 88.9% (P＞0.05) in entecavir-treated patients; the percentage of peripheral blood CD4⁺ cells in tenofovir-treated patients were(33.9±3.9)% and (38.6±5.6)%, significantly higher than , and the CD4⁺/CD8⁺ cell ratio were (1.2±0.1) and (1.5±0.1), significantly higher than [(1.0±0.0) and (1.3±0.1), respectively, P＜0.05] in entecavir-treated patients; during the 12-month observation period, the resistance rate in tenofovir-treated patients was 4.9%, not significantly different compared to 2.8% in entecavir-treated patients (x²=0.013,P=0.908). Conclusion The administration of tenofovir and entecavir in the treatment of CHB patients who do not respond to polyethylene glycol interferon-α could obtain a good clinical efficacy, while the tenofovir could improve immune functions, which might improve serological response and warrants further investigation.

Key words: Hepatitis B, Tenofovir, Entecavir, Pegylated interferon-α, Re-treatment

周冰清, 杨汉青, 蒋蓓莉. 替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎患者疗效比较研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 681-684.

Zhou Bingqing, Yang Hanqing, Jiang Beili. Re-treatment of chronic hepatitis B non-responders to pegylated interferon-α by tenofovir and entecavir[J]. Journal of Practical Hepatology, 2021, 24(5): 681-684.

参考文献

[1]Sekiba K, Otsuka M, Ohno M, et al. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. World J Gastroenterol, 2018, 24(21):2261-2268.
[2]Kang MK, Park JG. Tenofovir disoproxil fumarate-induced severe liver injury in a patient with chronic hepatitis B virus infection. Dig Liver Dis, 2018, 50(6):628-630.
[3]Rosenthal P, Ling SC, Belle SH, et al. Combination of entecavir/peginterferon alfa-2a in childrenwith hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection. Hepatology, 2019, 69(6):2326-2337.
[4]Pavlovic V, Yang L, Chan HL, et al. Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review andmeta-analysis of individual participant data. Antivir Ther, 2019, 24(2):133-140.
[5]Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68(4):672-681.
[6]Gokce O, Ozenirler S, Atak Yucel A, et al. Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol, 2018, 30(8):918-924.
[7]王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3):389-400.
[8]刘彦辰,张文露,胡源, 等.反向杂交法检测乙型肝炎病毒3种核苷(酸)类似物耐药突变.中华肝脏病杂志,2010,18(6):414-418.
[9]Tatsukawa Y, Tsuge M, Kawakami Y, et al. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in hbe-antigen-negative chronic hepatitis B patients: a pilot study. Antivir Ther, 2018, 23(8):639-646.
[10] Jindal A, Vyas AK, Kumar D, et al. Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitis B envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy. Hepatol Res, 2018, 48(6):451-458.
[11] Chen MB, Wang H, Zheng QH, et al. Comparative efficacy of tenofovir and entecavir in nucleostide analogue-naive chronic hepatitis B: A systematic review and meta-analysis. PLoS One, 2019, 14(11):e0224773.
[12] Mudaliar S, Liu K, Strasser SI. Surface antigen negative hepatitis B infection: the importance of screening before B cell-depleting therapy. Med J Aust, 2019, 210(10):442-443.
[13] Binka M,Butt ZA, Wong S, et al. Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada. World J Gastroenterol, 2018, 24(11):1216-1227.
[14] Lim JK, Nguyen MH, Kim WR, et al. Prevalence of chronic hepatitis B virus infection in the united states. Am J Gastroenterol, 2020, 115(9):1429-1438.
[15] Lin TC, Chiu YC, Chiu HC, et al. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol, 2018, 24(6):725-736.
[16] Tada T, Toyoda H, Yasuda S, et al. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleostide analogue therapy: an analysis using a markov chainmodel. Eur J Gastroenterol Hepatol, 2019, 31(11):1452-1459.
[17] 时红, 李向永, 朱建芸, 等. 恩替卡韦和替诺福韦酯治疗高病毒载量HBeAg阳性CHB的比较分析. 中华肝脏病杂志, 2017, 25(10):721-725.
[18] Zhang S, Guo H, Smith R. Dynamical analysis for a hepatitis B transmission model with immigration and infection age. Math Biosci Eng, 2018,15(6):1291-1313.
[19] Pandey A, Ezemenari S, Liaukovich M, et al. A rare case of pembrolizumab-induced reactivation of hepatitis B. Case Rep Oncol Med, 2018,2018:5985131.
[20] Shouman K, Prieto PG, Stino AM, et al. Serum creatine kinase in patients with neuromyelitis optica spectrum disorder. J Neuroimmunol, 2019, 330(15):87-89.
[21] Marson JW, Baldwin HE.The creatine kinase conundrum: a reappraisal of the association of isotretinoin, creatine kinase, and rhabdomyolysis. Int J Dermatol, 2020, 59(3):279-283.
[22] Zhou YH. Treatment of chronic hepatitis B infection, JAMA, 2018,320(11):1201.
[23] Lee T, Yang JJ, Eom J, et al. A single-center, single-blind study to evaluate the clinical sensitivity, specificity, and agreement between Elecsys Anti-HBc II and elecsys anti-HBc in a Korean population. J Clin Virol, 2018, 109:41-44.
[24] Katoonizadeh A, Motamed-Gorji N, Sharafkhah M, et al. Intra-familial transmission of chronic hepatitis B infection: A large population-based cohort study in northern Iran.Arch Iran Med, 2018,21(10):436-442.
[25] Lee SW, Kwon JH, Lee HL, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut, 2020, 69(7):1301-1308.
[26] Liem KS, Fung S, Wong DK, et al. Limited sustained response after stopping nucleostide analogues in patients with chronic hepatitis B: results from a randomised controlled trial. Gut, 2019, 68(12):2206-2213.

替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎患者疗效比较研究^*

Re-treatment of chronic hepatitis B non-responders to pegylated interferon-α by tenofovir and entecavir

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许政衡, 黄勇, 柯海霞, 李南, 马乙云. 慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 811-814.
[2]	季旻游, 李超, 赵兴忠, 武煦峰. 恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化患者疗效及对肠道菌群的影响^*[J]. 实用肝脏病杂志, 2021, 24(5): 641-644.
[3]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.
[4]	吴凤萍, 鲁瑞, 刘怡欣, 王怡恺, 田燕, 张欣, 贾晓黎, 党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 677-680.
[5]	杨永汉, 路萍, 孟庆宁, 张枫婕. 增强MRI T1 mapping定量评估慢性乙型肝炎患者肝纤维化程度效能分析[J]. 实用肝脏病杂志, 2021, 24(5): 685-688.
[6]	杨艳秋, 程颢, 冯敏. 肝脏剪切波弹性成像对慢性乙型肝炎患者肝纤维化的评估价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 480-483.
[7]	吴慧, 宋波, 吕承秀, 田文君, 牛家峰. 慢性乙型肝炎患者血清内质网应激指标变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(4): 484-487.
[8]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.
[9]	安西全, 李燕, 孟根才次克. 替诺福韦联合索拉非尼治疗乙型肝炎相关中晚期原发性肝癌患者临床观察[J]. 实用肝脏病杂志, 2021, 24(4): 600-602.
[10]	黄永群, 黄润强, 熊平安. 替诺福韦酯联合双重免疫方案阻断HBV携带孕妇母婴病毒传播效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 331-334.
[11]	徐文婷, 张继红, 韦冬珏, 李巍. 替诺福韦补救治疗rtM204位点突变的慢性乙型肝炎患者效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 335-338.
[12]	王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.
[13]	陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.
[14]	张思薇, 孔银, 刘天府, 刘元元, 麻爱娣, 李永芳, 李娟, 张岭漪. 肝脏硬度检测联合吲哚菁绿滞留率测定对血清转氨酶正常或轻度升高的慢性乙型肝炎患者肝组织学病变进展的预测价值[J]. 实用肝脏病杂志, 2021, 24(2): 184-187.
[15]	杨永启, 郭彦东, 李鸿彬. 慢性乙型肝炎患者肠粘膜病变观察[J]. 实用肝脏病杂志, 2021, 24(2): 188-191.